The Huntington Study Group (HSG) and National Institute for Neurologic Disease and Stroke (NINDS) has announced that their 2CARE clinical trial, examining coenzyme Q10 for the treatment of Huntington disease patients was terminated early because of futility. For more information on the termination of the 2CARE trial please see the HSG announcement here.
